Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell-derived erythroid cells mediate long-term systemic protein delivery.

Alex H Chang1, Matthias T Stephan, Michel Sadelain

  • 1Laboratory of Gene Transfer and Gene Expression, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Nature Biotechnology
|July 18, 2006
PubMed
Summary

Erythroid cells can deliver therapeutic proteins long-term in vivo. This study shows red blood cell-mediated delivery of human factor IX corrects hemophilia B in mice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

Blood cancer discovery·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same author

Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Frontiers in immunology·2026
Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026

Area of Science:

  • Biotechnology
  • Hematology
  • Gene Therapy

Background:

  • Protein replacement therapy is a cornerstone for treating genetic disorders like hemophilia B.
  • Current protein delivery methods face challenges including short half-life, immunogenicity, and high costs.

Purpose of the Study:

  • To evaluate the potential of erythroid cells for sustained, systemic therapeutic protein delivery in vivo.
  • To assess the efficacy of targeting human factor IX (hFIX) expression to erythropoiesis for hemophilia B treatment.

Main Methods:

  • Targeting hFIX expression to late-stage erythropoiesis in a mouse model of hemophilia B.
  • Measuring hFIX secretion levels and biological activity.
  • Evaluating phenotypic correction of the bleeding disorder.

Related Experiment Videos

Main Results:

  • Erythroid cell-mediated delivery achieved significantly higher long-term hFIX secretion (>tenfold) compared to a ubiquitous promoter.
  • Erythroid cell-derived hFIX was biologically active and corrected the hemophilia B phenotype.
  • This approach demonstrated resistance to transcriptional silencing.

Conclusions:

  • Erythroid cells are a viable platform for long-term, therapeutic protein delivery in vivo.
  • Red cell-mediated protein delivery offers advantages such as immune tolerance and reduced oncogenesis risk.
  • Therapeutic protein delivery via erythropoiesis is a promising strategy for treating genetic bleeding disorders.